Form 4: Corcept Therapeutics Director Acquires Stock Options

Corcept Therapeutics Director Kimberly Park acquired 12,500 stock options with an exercise price of $59.69, vesting over one year.

Summary

• Kimberly Park, a Director at Corcept Therapeutics Inc., acquired 12,500 stock options on May 21, 2026.
• The stock options have an exercise price of $59.69 per share.
• These options are exercisable ratably in equal installments over a one-year period, starting from May 21, 2026, contingent upon continued service.
• The underlying securities are 12,500 shares of Corcept Therapeutics' Common Stock.
• The transaction was reported on May 26, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard stock option grant to a director, indicating continued incentive and potential future value realization.

Positives

• Director's acquisition of stock options indicates confidence in the company's future prospects.
• The vesting schedule over one year suggests a commitment to continued service and alignment with shareholder interests.

Future Outlook

The stock options are exercisable over a one-year period starting May 21, 2026, and expire on May 21, 2036, indicating a long-term outlook for the company's performance.

Industry Context

StockSavvy.ai notes that insider option grants, particularly to directors, are common in the biotechnology and pharmaceutical sectors as a means of executive compensation and aligning management's interests with long-term company growth and shareholder value.

Stakeholder Impact

• Shareholders: The grant of options to a director aligns their interests with shareholders, potentially leading to decisions that enhance share value.
• Employees: This type of compensation for directors is standard and does not directly impact other employees unless it reflects broader compensation strategies.

Next Steps

• The stock options will vest ratably over a one-year period.
• The reporting person may exercise the vested options until the expiration date of May 21, 2036.

Key Dates

Keywords

Corcept Therapeutics, CORT, Form 4, Stock Options, Insider Transaction, Beneficial Ownership, Director, Securities Exchange Act